News

The start of field-based commercialization efforts for Xalkori is part of the company’s aim to bring treatment options for challenging cancers to patients. In the US, Xalkori is

EpiTherapeutics has developed a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. Gilead Research and Development executive vice-president and

Venetoclax is an inhibitor of the B-cell lymphoma-2 (BCL-2) protein, which AbbVie is currently developing in partnership with Genentech and Roche. It is designed to selectively inhibit the

Located in Kendall Square, the new Lilly Cambridge Innovation Center will allow leading life science experts and organizations to explore how emerging technologies and connectivity can advance drug

The program includes two replicate studies evaluating 48 week viral suppression with a two drug regimen combining dolutegravir and rilpivirine in HIV patients who have already achieved viral

The transaction, which has been unanimously approved by Boards of Directors from both companies, will strengthen Alexion’s business in developing and commercializing transformative therapies for patients with devastating

According to the company, the decision taken to retain existing holding in ViiV Healthcare reflects on its updated strong positive outlook. ViiV Healthcare, is a joint venture with

The world market for HAE reached $1.1bn in 2014 and has been growing at an average rate of 44% in the last three years, and analysts expect the

EirGen, based in Waterford, Ireland, was founded by two former executives of IVAX Pharmaceuticals, Tom Brennan and Patsy Carney. The company, situated in a state of the art